0001213900-23-025698.txt : 20230403 0001213900-23-025698.hdr.sgml : 20230403 20230331184136 ACCESSION NUMBER: 0001213900-23-025698 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230331 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230403 DATE AS OF CHANGE: 20230331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABVC BIOPHARMA, INC. CENTRAL INDEX KEY: 0001173313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260014658 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40700 FILM NUMBER: 23789771 BUSINESS ADDRESS: STREET 1: 44370 OLD WARM SPRINGS BLVD. CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: 510-668-0881 MAIL ADDRESS: STREET 1: 44370 OLD WARM SPRINGS BLVD. CITY: FREMONT STATE: CA ZIP: 94538 FORMER COMPANY: FORMER CONFORMED NAME: American BriVision (Holding) Corp DATE OF NAME CHANGE: 20160111 FORMER COMPANY: FORMER CONFORMED NAME: METU BRANDS, INC. DATE OF NAME CHANGE: 20150908 FORMER COMPANY: FORMER CONFORMED NAME: ECOLOGY COATINGS, INC. DATE OF NAME CHANGE: 20080821 8-K/A 1 ea176287-8ka_abvcbio.htm AMENDMENT TO FORM 8-K
0001173313 true 0001173313 2023-03-31 2023-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K/A

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 31, 2023

 

ABVC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40700   26-0014658
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

44370 Old Warm Springs Blvd.

Fremont, CA

   94538
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number including area code: (510) 668-0881

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ABVC   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

  

Item 2.02 Results of Operations and Financial Condition

 

On March 31, 2023, ABVC BioPharma, Inc. (the “Company”) filed a Form 8-K to report its audited financial results for the year ended December 31, 2023 (the “Original 8K”) and attached a copy of a press release thereto (the “Original PR, together with the Original 8K, the “Original Filing”). We are filing this amendment to amend certain information contained in the Original Filing. A copy of the revised press release is being filed as Exhibit 99.1 attached hereto and is incorporated by reference herein. The information disclosed under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company’s securities in any state in which such offer, solicitation or sale would be unlawful.

 

Item 8.01Other Events.

The Company issued a press release on March 31, 2023 disclosing the financial results. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number		   Exhibit
99.1   Press Release
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 2 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABVC BioPharma, Inc.
     
March 31, 2023 By: /s/ Howard Doong
    Howard Doong
    Chief Executive Officer

 

 3 

 EX-99.1 2 ea176287ex99-1_abvcbio.htm PRESS RELEASE

Exhibit 99.1

 

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

 

FREMONT, CA, March 31, 2023 -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022.

 

Full Year 2022 Financial Results

 

All comparisons are made on a year-over-year basis.

 

●Revenues. We generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively. The increase of $613,986, or approximately 173%, was primarily caused by the increase in contract services with Rgene.

 

●Operating Expenses. Our operating expenses were $15,797,780 in the year ended December 31, 2022, as compared to $12,056,679 in the year ended December 31, 2021. Such increase in operating expenses was mainly attributable to the increase in stock-based compensation and selling, general and administrative expenses by $2,051,449 which relates to costs in conjunction with our public offering and our recent stock issuances, as well as increasing research and development expenses of $1,689,652 to continue to develop our pipeline.

 

●Other Income (expense). The other expense was $400,184 in the year ended December 31, 2022 as compared to other income of $495,141 in the year ended December 31, 2021. The change was principally caused by the increase in interest expense, while being offset by the increase in interest income for the year ended December 31, 2022, and loss on investment in equity securities and decrease in government grant income for the year ended December 31, 2022.

 

●Net Loss. The net loss was $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021. The Company’s net loss increased by $4,276,523 or approximately 36% during the year ended December 31, 2021 from 2021.

 

●Working (Deficit) Capital. Working deficit as of December 31, 2022 was $2,832,282, compared to working capital of $3,691,470 as of December 31, 2021, primarily as a result of a decrease in net cash from financing activities. The net cash provided by financing activities decreased by $5,981,625, due to the increase in proceeds from short-term loans, partially offset by the decrease in issuance of common stock through up-list, as well as decrease in payment of offering costs, repayment of convertible notes and notes payable, and proceeds from long-term loans during the year ended December 31, 2021.

 

●Cash and Cash Equivalents. The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2022 and 2021, the Company’s cash and cash equivalents amounted $85,265and $5,828,548, respectively.

 

 

 

 

Fourth Quarter 2022 Highlights

 

ABV-1701 Vitargus®:

 

Vitargus is intended to be the first biodegradable vitreous substitute to facilitate retina reattachment surgery. The company expects to complete Phase II trials of Vitargus in Thailand, Australia and Taiwan by the end of 2023, the successful completion of which is expected to lead to distribution agreements in Asia soon thereafter.   ABVC expects the study to further demonstrate that Vitargus has properties that eliminate the need for post-surgery patient face-down positioning and can provide greater patient comfort and visual acuity during the surgical recovery period.

 

ABV-1505 ADHD:

 

The company’s ADHD medicine ABV-1505, is currently in Phase II, part 2, clinical trials at five prestigious medical centers in Taiwan. A Phase II, part 2 study will begin at the University of California, San Francisco (UCSF) Medical Center in the next few months. This study is expected to eventually enroll approximately 100 patients in Taiwan and the United States.

 

Following the May 2022 reports of the first subject treated in Taiwan, 42 subjects have been enrolled in the study from a total of 64 subjects screened. 36 of the enrolled participants have already completed the 8-week treatment in accordance with the study design.

 

ABV-1601 Cancer Patient Depression:

 

A Phase I study of ABV-1601 for treating depression in cancer patients is expected to begin in the first quarter of 2023 at the Cedars-Sinai Medical Center (CSMC, West Hollywood CA). The Phase I study is open label and will be conducted with 12 cancer patients with moderate to severe depressive symptoms. The main objective of the study is to evaluate the safety of PDC-1421, the primary active ingredient in ABV-1601 in cancer patients. The Phase II study is to determine the most effective dosages using a randomized, double-blind, non-inferiority protocol of PDC-1421 vs Wellbutrin XL. ABVC expects to initiate the Phase II study in the fourth quarter of 2023 and then compare the results to Wellbutrin XL, a commonly used medicine to treat cancer patients suffering with depression.

 

ABV-1504 Major Depressive Disorder:

 

ABVC’s MDD medicine, ABV-1504, has successfully completed Phase II at the Stanford University Medical Center and five major medical centers in Taiwan. Later this year, with the help of Dr. Maurizio Fava and Dr. Thomas Laughren, the company expects to conclude discussions with the US FDA on acceptable protocols for Phase III trials for MDD, allowing ABVC to seek potential distribution partners active in manufacturing and distributing Central Nervous System (CNS) medicines.

 

2

 

 

“We are delighted with our remarkable accomplishments and meaningful progress in 2022,” said Dr. Howard Doong, M.D., Ph.D., Chief Executive Officer of ABVC BioPharma. “I am pleased that ABV-1504 ADHD Phase II, part II study is making substantial progress at five Taiwan study sites and UCSF and expecting to be completed in 2023, that Phase I studies of ABV-1601 for treating depression in cancer patients is being initiated at CSMC in US, and with the progress of End-of-Phase II meeting preparation for ABV-1504 (MDD) with Dr. Maurizio Fava and Dr. Thomas Laughren of Clinical Trials Network and Institute, (CTNI). In addition, ABV-1701 Vitargus, a hydrogel we developed to make retina reattachment surgery more comfortable and successful for patients, has shown advantages over existing devices available to surgeons in Phase I clinical study completed in Australia in 2018, prompting us to start a Phase II trial in Australia and Thailand in 2022. The study has received the approvals from both Australian TGA and Thai FDA with patient enrollment planned in early Q2 of 2023. We remain excited about our ongoing research initiatives and look forward to expanding our product pipeline in the future.”

 

About ABVC BioPharma

 

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct global clinical trials through Phase III. 

 

Forward-Looking Statements

 

Clinical trials are in early stages, and there is no guarantee that any specific outcome will be achieved. This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

 

Contact

 

Leeds Chow, CFO

Email: leedschow@ambrivis.com

 

3

 

 

ABVC BIOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

   December 31,   December 31, 
   2022   2021 
ASSETS        
Current Assets          
Cash and cash equivalents  $85,265   $5,828,548 
Restricted cash and cash equivalents   1,306,463    736,667 
Accounts receivable, net   98,325    280,692 
Accounts receivable - related parties, net   757,343    145,399 
Due from related parties   513,819    - 
Inventories, net   -    25,975 
Short-term investments   75,797    108,147 
Prepaid expense and other current assets   150,235    528,354 
Total Current Assets   2,987,247    7,653,782 
           
Property and equipment, net   573,978    525,881 
Operating lease right-of-use assets   1,161,141    1,471,899 
Long-term investments   842,070    932,755 
Deferred tax assets, net   117,110    981,912 

Prepaid expenses – noncurrent

   135,135    119,309 
Security deposits   58,838    41,157 

Prepayment for long-term investments

   2,838,578    1,153,155 
Due from related parties – noncurrent   1,141,378    818,183 
Total Assets  $9,855,475   $13,698,033 
           
LIABILITIES AND EQUITY          
Current Liabilities          
Short-term bank loans  $1,893,750   $1,640,000 
Accrued expenses and other current liabilities   2,909,587    1,300,803 
Advance from customers   10,985    10,985 
Operating lease liability – current portion   369,314    347,100 
Due to related parties   635,893    393,424 
Total Current Liabilities   5,819,529    3,692,312 
           
Tenant security deposit   7,980    10,580 
Operating lease liability – noncurrent portion   791,827    1,124,799 
Total Liabilities   6,619,336    4,827,691 
           
COMMITMENTS AND CONTINGENCIES          
Equity          
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding   -    - 
Common stock, $0.001 par value, 100,000,000 authorized, 32,857,329 and 28,926,322 shares issued and outstanding as of December 31, 2022 and 2021, respectively   32,857    28,926 
Additional paid-in capital   67,907,479    58,113,667 
Stock subscription receivable   (1,354,440)   (2,257,400)
Accumulated deficit   (54,904,439)   (38,481,200)
 Accumulated other comprehensive income   517,128    539,660 
Treasury stock   (9,100,000)   (9,100,000)
Total Stockholders’ equity   3,098,585    8,843,653 
Noncontrolling Interest   517,128    26,689 
Total Equity   3,236,139    8,870,342 
           
Total Liabilities and Equity  $9,855,475   $13,698,033 

  

4

 

 

ABVC BIOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

    

Year Ended December 31,

 
    2022    2021 
Revenue  $969,783   $355,797 
           
Cost of revenue   286,415    5,086 
           
Gross profit   683,368    350,711 
           
Operating expenses          
Selling, general and administrative expenses   6,067,545    5,746,119 
Research and development expenses   2,693,457    1,003,805 
Stock based compensation   7,036,778    5,306,755 
Total operating expenses   15,797,780    12,056,679 
           
Loss from operations   (15,114,412)   (11,705,968)
           
Other income (expense)          
Interest income   187,817    43,196 
Interest expense   (293,968)   (227,210)
Operating sublease income   107,150    134,576 
Operating sublease income - related parties   -    4,800 
Impairment loss   (110,125)   - 
Investment loss   (7,446)   - 
Gain/Loss on foreign exchange changes   (259,463)   426,316 
Gain/Loss on investment in equity securities   -    (269,844)
Other income (expense)   (24,149)   22,409 
Government grant income   -    360,898 
Total other income (expenses)   (400,184)   495,141 
           
Loss before provision for income tax   (15,514,596)   (11,210,827)
           
Provision for income tax expense    797,778    825,024 
           
Net loss   (16,312,374)   (12,035,851)
           
Net loss attributable to noncontrolling interests   110,865    802,962 
           
Net loss attributed to ABVC and subsidiaries   (16,423,239)   (12,838,813)
Foreign currency translation adjustment   (22,532)   (25,200)
Comprehensive loss  $(16,445,771)  $(12,864,013)
           
Net loss per share:          
Basic and diluted  $(0.52)  $(0.51)
           
Weighted average number of common shares outstanding:          
Basic and diluted   31,664,660    25,053,522 

 

5

 

 

ABVC BIOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 2022 AND 2021

 

   2022   2021 
Cash flows from operating activities        
Net loss  $(16,312,374)  $(12,035,851)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   23,799    11,993 
Stock based compensation   7,036,778    5,306,755 
Loss on investment in equity securities   -    269,844 
Inventory allowance for valuation losses   25,975    - 
Provision for doubtful accounts, net of recovery   184,589    - 
Government grant income   -    (360,898)
Other non-cash income and expenses   32,350    - 
Impairment of prepaid expenses   110,125    - 
Deferred tax   864,802    824,199 
Changes in operating assets and liabilities:          
Decrease (increase) in accounts receivable   (614,166)   (120,980)
Decrease (increase) in prepaid expenses and other current assets   238,092    (357,276)
Decrease (increase) in due from related parties   (837,014)   (595,037)

Decrease (increase) in inventories

   -    (25,830)
Increase (decrease) in accounts payable   -    (23,044)
Increase (decrease) in accrued expenses and other current liabilities   1,608,784    (173,151)
Increase (decrease) in advanced from customers   -    (1,085)
Increase (decrease) in tenant security deposit received   (2,600)   - 
Increase (decrease) in due to related parties   242,469    (317,358)
Net cash used in operating activities   (7,398,391)   (7,597,719)
           
Cash flows from investing activities          
Purchase of investments   -    (107,547)
Purchase of equipment   (119,692)   (17,503)
Prepayment for equity investment   (1,601,992)   (680,916)
Net cash used in investing activities   (1,721,684)   (805,966)
           
Cash flows from financing activities          
Issuance of common stock   3,663,925    11,119,452 
Payment for offering costs   -    (850,429)
Repayment of convertible notes   -    (306,836)
Repayment of short-term loan   -    (100,000)
Repayment of notes payable   -    (107,400)
Proceeds from long-term loan   -    236,498 
Proceeds from short term loan   350,000    - 
Proceeds from short term borrowings from third parties   -    4,265 
Net cash provided by financing activities   4,013,925    9,995,550 
           
Effect of exchange rate changes on cash and cash equivalents and restricted cash   (67,337)   (28,021)
           
Net increase in cash and cash equivalents and restricted cash   (5,173,487)   1,563,844 
           
Cash and cash equivalents and restricted cash          
Beginning   6,565,215    5,001,371 
Ending  $1,391,728   $6,565,215 
           
Supplemental disclosure of cash flows          
Cash paid during the year for:          
Interest expense paid  $285,465   $333,873 
Income taxes paid  $1,600   $- 
Non-cash financing and investing activities          
Common shares issued for debt conversion  $-   $2,693,548 

 

 

6

 

 

 EX-101.SCH 3 abvc-20230331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 abvc-20230331_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 abvc-20230331_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Mar. 31, 2023
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description On March 31, 2023, ABVC BioPharma, Inc. (the “Company”) filed a Form 8-K
Document Period End Date Mar. 31, 2023
Entity File Number 001-40700
Entity Registrant Name ABVC BIOPHARMA, INC.
Entity Central Index Key 0001173313
Entity Tax Identification Number 26-0014658
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 44370 Old Warm Springs Blvd.
Entity Address, City or Town Fremont
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94538
City Area Code (510)
Local Phone Number 668-0881
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ABVC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 ea176287-8ka_abvcbio_htm.xml IDEA: XBRL DOCUMENT 0001173313 2023-03-31 2023-03-31 iso4217:USD shares iso4217:USD shares 0001173313 true 8-K/A 2023-03-31 ABVC BIOPHARMA, INC. NV 001-40700 26-0014658 44370 Old Warm Springs Blvd. Fremont CA 94538 (510) 668-0881 false false false false Common Stock, par value $0.001 per share ABVC NASDAQ false On March 31, 2023, ABVC BioPharma, Inc. (the “Company”) filed a Form 8-K EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #&5?U8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " QE7]6K1&=4.T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OIVG$0^CVLN))07!!\1:2V=U@DX9DI-VW-XV[740?P&-F_GSS M#4RG@]1CQ.[ (2FC2,$"K,)*9'UGM-01%8WQC#=ZQ8?/.!28T8 #.O24@-<<6+], M#*=YZ. *6&"$T:7O IJ56*I_8DL'V#DY)[NFIFFJ)U%R>0<.;T^/+V7=ROI$ MRFO,OY*5= JX89?)KV)[OWM@?=NTHFI$)?BN;>4MEX*_+ZX__*[";C1V;_^Q M\46P[^#77?1?4$L#!!0 ( #&5?U:97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M,95_5K5[()^@! :!$ !@ !X;"]W;W)K'P5K(=Q4RILE''"5J:(5:IU>VK?R0Q50U1 M6JZUO_',EZ$V-^S1(*5+-F/ZCW0J8647*@&/6:*X2(ADBZ$U=J]NO(XQR)]X MY6RM#JZ)VS> B&EF.(6,1\;20H_%NQ"8LBHP0<_^Q$K>([C>'A]5[] M/M\\;&9.%9N(Z(T'.AQ:?8L$;$&S2#^+]3>VVU .Z(M(Y7_)>OMLNVT1/U-: MQ#MC((AYLOU//W:..##HM8X8>#L#+^?>?E%.>4LU'0VD6!-IG@8U$5&%ZNU\(PR%_CN=(2 O5W%=%6H5VM8++W2J749T,+TE,QN6+6Z.L7M^M< M(WRM@J^%J8]NA9]!+FKRLDE9%1QNWK_X;H\1C':!T49UQL 0Y!SW$5U6<>#V M6F8,P>@4&)T3,6Z9\B5/38%5T> R3PF!//+#(I$:9'SS.B$W7$Q#"B77( ^) MWR1G.F3DZY>^YSG7$Q&G--GD*_?Z_)<%CUA *#$E2L#-R.ZZQ>ZZI\5ZRB07 M ;E+ @*U51EV7*FHDKHRZ15H/53P+M%<;\@];)H\9O&\NG1Q#<=Q+]I.SW$0 MGG[!TS^%YYDMN2E<\-DCC2L=A>MLP_[P-/TV?OXYAK _3IH(WF6!=WD*W@2" M*6D$R12P#_*=;:H <24'O.;V6BT7BZ+KE$W7.07LA7Z0AP#H^(+[-)]2QZ-: M(^EU+X"QW>WT,<*#L>">0@CU)V0J9 [7(#,-=4"$)!.1@4_!M2*H#'>-^N,K M!ED.#1?M^7O(<1! QU>-_07Y <^1IZ2:#)=LMUL]ASQ% 7F##D1FJ>3)4I&; M:!5@&>F6@\3%1\%GYHE9@4=?Q+JRA=;(W4L6BT1C:.5P!I5\N J=3Q> M.0P\O'-/);OPP3T,*FQ[QH33%9R&GQ:+ZOC5Z-62E4/ P]OT_\@>E,J K!80 MEZT%/'AKP+OU"]=P$A(+XGIG\W,R8WX&^58YWVN43'["^)UIX;\W2$HE6=$H M8^17IPECE:2P705G4A2[G $>WK1?) U,^LTV\5Q4)E^-@#DO821ER_?P]KSW M&+G[\$.:+-G1 UR-T.-X=CO^'6,J>[UW4J^_BYE<&B_]!@HZ)+N3?R4;+G@T MW^R#]V;S&P2="PXMY?ADR"K5@'H#/ M%T+H_<*\G1<_KHS^!5!+ P04 " QE7]6GZ ;\+$" #B# #0 'AL M+W-T>6QEO%D MN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY# M;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? M KP(&K XU7=>&18/QA<0 M&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH M!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)? MA+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+ M"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TU MMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K% M.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$# M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@" MIQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " QE7]6EXJ[', M 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D! M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\= MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( #&5 M?U:JQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P M%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6V MG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%* M0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/ MJ!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09# MK+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPY MZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " QE7]6)!Z;HJT M #X 0 &@ 'AL+U]R96QS+W=O[IFBG#S^ M0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@ MXLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ ,95_5F60 M>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5; M)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B= M]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T M.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JK MA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$# M(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[ M04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%0 M2P$"% ,4 " QE7]6!T%-8H$ "Q $ @ $ M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( #&5?U:M$9U0[0 "L" 1 M " :\ !D;V-0&UL4$L! A0#% @ ,95_5K5[()^@! :!$ !@ M ("!# @ 'AL+W=O(, !X;"]S='EL97,N M>&UL4$L! A0#% @ ,95_5I>*NQS $P( L ( ! MO@\ %]R96QS+RYR96QS4$L! A0#% @ ,95_5JK$(A8S 0 (@( \ M ( !IQ 'AL+W=OP2 !;0V]N=&5N=%]4>7!E&UL4$L%!@ ) D */@( #84 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abvcpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea176287-8ka_abvcbio.htm abvc-20230331.xsd abvc-20230331_lab.xml abvc-20230331_pre.xml ea176287ex99-1_abvcbio.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea176287-8ka_abvcbio.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea176287-8ka_abvcbio.htm" ] }, "labelLink": { "local": [ "abvc-20230331_lab.xml" ] }, "presentationLink": { "local": [ "abvc-20230331_pre.xml" ] }, "schema": { "local": [ "abvc-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ABVC", "nsuri": "http://abvcpharma.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ea176287-8ka_abvcbio.htm", "contextRef": "From2023-03-31to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://abvcpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ea176287-8ka_abvcbio.htm", "contextRef": "From2023-03-31to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001213900-23-025698-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-025698-xbrl.zip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�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